Vor Biopharma Inc.
VOR evidence brief
What we can confirm
- BioSniper Score:
- 4.6 / 10
- Market Cap:
- $1.21B
- Lead Asset:
- telitacicept (Phase 3)
What it means
What to watch
Prepared research question
What matters most for VOR—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · VOR
Vor Biopharma Inc. (VOR) is a clinical-stage biotechnology company developing telitacicept, a dual BAFF/APRIL inhibitor, for autoimmune diseases, with Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease, and a separate CD33-directed CAR-T program for AML.
Key risk: Negative equity
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 2 clinical trials for Vor Biopharma Inc..
Vor Biopharma Inc. (VOR) is a clinical-stage biotechnology company developing telitacicept, a dual BAFF/APRIL inhibitor, for autoimmune diseases, with Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease, and a separate CD33-directed CAR-T program for AML.
- Cash and equivalents of $107.9M as of 2026-06-30 [sec].
- Net income of -$62.8M for the period ending 2026-06-30 [sec].
- Shareholders' equity of -$200.2M as of 2026-06-30 [sec].
- Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis completed enrollment; topline results expected in first half of 2027 [news · 2026-09-08].
- Phase 3 UPSTREAM SjD trial for telitacicept in primary Sjögren's disease is ongoing [news · 2026-08-11].
What works
- Telitacicept has completed enrollment in a global Phase 3 trial (UPSTREAM MG) for generalized myasthenia gravis, with topline results expected in 1H27, indicating progress toward a potential registrational data package [news · 2026-09-08].
- The company has expanded its telitacicept franchise into ocular myasthenia gravis with a planned registrational trial (UPSTREAM oMG), broadening the addressable indication [news · 2026-09-08].
- Vor Biopharma has a cash runway into early 2029, based on its cash and investment balance as of mid-2026, providing financial flexibility for ongoing clinical programs [news · 2026-08-11].
What to weigh
- The company has negative shareholders' equity of -$200.2M as of 2026-06-30, indicating that liabilities exceed assets [sec].
- Vor Biopharma reported a net loss of -$62.8M for the period ending 2026-06-30, reflecting ongoing operating expenses without product revenue [sec].
- The company acknowledges it will need to raise additional capital to fund future operations, and its cash runway estimate is based on assumptions that may prove incorrect [sec_mda · as of 2026-08-11].
- Telitacicept faces a competitive landscape including monoclonal antibodies targeting BAFF-R, CD40-CD40L signaling, and FcRn from companies such as Alexion, Amgen, Argenx, and others [pipeline].
From the filings
Quoted directly from source documents.
Phase 3 UPSTREAM MG trial enrollment completed
“Vor Completes Enrollment of Global Phase 3 UPSTREAM MG Trial”
News · September 8, 2026
Risks & what to watch (4)›
Key risks
- Negative equity — Shareholders' equity of -$200.2M as of 2026-06-30 indicates liabilities exceed assets [sec].
- No product revenue — Net loss of -$62.8M for period ending 2026-06-30 reflects ongoing R&D spending without commercial sales [sec].
- Future capital needs — Company states it will need to raise additional capital to fund planned operations [sec_mda · as of 2026-08-11].
- Clinical trial uncertainty — Development timelines and outcomes are subject to numerous risks outside company control [sec_mda · as of 2026-08-11].
What to watch
- Topline results from the Phase 3 UPSTREAM MG trial for telitacicept in generalized myasthenia gravis, expected in first half of 2027 [news · 2026-09-08].
- First patient dosing in the Phase 3 UPSTREAM oMG trial for ocular myasthenia gravis, anticipated in first half of 2027 [news · 2026-09-08].
- Progress of the Phase 3 UPSTREAM SjD trial for telitacicept in primary Sjögren's disease [news · 2026-08-11].
- Any future capital raises or financing activities, given the company's negative equity and stated need for additional capital [sec_mda · as of 2026-08-11].
Sources: News · Pipeline · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run Vor Biopharma Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Vor Biopharma Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$63M
Lead: Phase 3
3 candidates
No upcoming catalysts tracked
0 buys · 4 sells (180d)
Pipeline
Regulatory
Financials
Short Interest
as of Apr 20, 2026- % of float
- 12.7%
- Days to cover
- 5.4
- Shares short
- 5,687,983
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
VOR short interestGovernance
Frequently asked questions
What is the AI investment thesis for Vor Biopharma Inc.?
Vor Biopharma Inc. (VOR) is a clinical-stage biotechnology company developing telitacicept, a dual BAFF/APRIL inhibitor, for autoimmune diseases, with Phase 3 trials in generalized myasthenia gravis and primary Sjögren's disease, and a separate CD33-directed CAR-T program for AML.
What is Vor Biopharma Inc.'s lead drug candidate?
Vor Biopharma Inc.'s most advanced tracked candidate is telitacicept (Phase 3) for Generalized Myasthenia Gravis; Primary Sjogren's Disease.
Who is the CEO of Vor Biopharma Inc.?
Dr. Jean-Paul Kress M.D. is the chief executive officer of Vor Biopharma Inc. (VOR).
Where is Vor Biopharma Inc. headquartered?
Vor Biopharma Inc. (VOR) is headquartered in Boston, MA, United States.
What therapeutic areas does Vor Biopharma Inc. focus on?
Vor Biopharma Inc. develops therapies across Oncology, Neurology, Immunology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.